« Previous
Next »
Clinical Gastroenterology and Hepatology
Volume 10, Issue 1
, Pages 46-51
, January 2012
Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model
To access this article, please choose from the options below
Conflicts of interest These authors disclose the following: Dr Siegel serves as a consultant to Abbott Laboratories, UCB, and Elan and has delivered CME talks for Merck and Abbott Laboratories. Dr Sands serves as a consultant to Abbott Laboratories, Centocor, and UCB. The remaining authors disclose no conflicts.
Funding Dr Siegel is supported by a CCFA career development award and by grant number K23DK078678 from the National Institute of Diabetes and Digestive and Kidney Diseases.
PII: S1542-3565(11)01021-4
doi: 10.1016/j.cgh.2011.09.017
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Clinical Gastroenterology and Hepatology
Volume 10, Issue 1
, Pages 46-51
, January 2012

